Results 291 to 300 of about 28,689 (318)
Some of the next articles are maybe not open access.
Ruxolitinib: A New Treatment for Myelofibrosis
Clinical Journal of Oncology Nursing, 2013Myelofibrosis (MF) is a blood cancer characterized by fibrotic bone marrow and altered hematopoiesis. Although the prevalence of MF is low, its severe symptoms have a significantly negative impact on patient quality of life, and its ability to transform into leukemia increases morbidity.
Emily W. Lowery, Susan M. Schneider
openaire +3 more sources
2017
Ruxolitinib (Jakafi, Jakavi, Incyte, Novartis) is a cyclopentylproprionitrile derivative tyrosine kinase inhibitor (TKI) that targets with high selectivity a new class of tyrosine kinases represented by JAK1 and JAK2, which are inhibited at IC50 of 3.3 and 2.8 nM, respectively. Lower activity is expressed by this drug on TYK2 (19 nM), and much lower on
openaire +2 more sources
Ruxolitinib (Jakafi, Jakavi, Incyte, Novartis) is a cyclopentylproprionitrile derivative tyrosine kinase inhibitor (TKI) that targets with high selectivity a new class of tyrosine kinases represented by JAK1 and JAK2, which are inhibited at IC50 of 3.3 and 2.8 nM, respectively. Lower activity is expressed by this drug on TYK2 (19 nM), and much lower on
openaire +2 more sources
Ruxolitinib for the treatment of primary myelofibrosis
American Journal of Health-System Pharmacy, 2014The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety profile of ruxolitinib for the treatment of primary myelofibrosis are reviewed.Ruxolitinib, an oral tyrosine kinase inhibitor that targets the Janus-associated kinases (JAKs) 1 and 2, has been recently approved for the treatment of patients with intermediate- or high ...
openaire +3 more sources
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Opzelura should not be reimbursed by public drug plans for the topical treatment of mild to moderate atopic dermatitis (AD) in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids [TCS],
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Opzelura should not be reimbursed by public drug plans for the topical treatment of mild to moderate atopic dermatitis (AD) in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids [TCS],
openaire +1 more source
Ruxolitinib Discontinuation Syndrome
American Journal of Therapeutics, 2020Nnamdi Chukwuka +2 more
openaire +2 more sources
Ruxolitinib: A Review in Polycythaemia Vera
Drugs, 2015Ruxolitinib (Jakavi(®), Jakafi(®)) is an orally administered, first-in-class Janus Kinase (JAK) 1 and 2 inhibitor that was recently approved for the treatment of patients with polycythaemia vera (PV) who have responded inadequately to or are intolerant of hydroxyurea. By inhibiting JAK 1 and 2, ruxolitinib reduces hyperactive JAK-signal transducers and
openaire +3 more sources
Ruxolitinib induced leukocytoclastic vasculitis
Medicina Clínica, 2021Atakan Turgutkaya, İrfan Yavaşoğlu
openaire +2 more sources
Treatment of dermatomyositis with ruxolitinib
Dermatologic Therapy, 2015Torello Lotti +2 more
openaire +3 more sources